ORIC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oric Pharmaceuticals Inc (ORIC) is not a strong buy for a beginner investor with a long-term strategy at this moment. Despite bullish analyst ratings and a positive technical setup, the lack of significant financial growth, insider and hedge fund selling, and no recent positive news or congress trading data make it prudent to hold off on investing right now.
The technical indicators are moderately bullish. The MACD is positive and contracting, suggesting a potential upward momentum. The RSI is neutral at 77.063, and the moving averages show a bullish trend (SMA_5 > SMA_20 > SMA_200). The stock is trading above key support levels, with resistance at R1: 14.046 and R2: 14.86.
Analysts have raised price targets recently, with expectations of a catalyst-rich period in the next 12 months. ORIC-944 is seen as a potential best-in-class treatment for prostate cancer, which could drive value creation.
Hedge funds and insiders are selling heavily, with insider selling up 773.65% in the last month. The company's financial performance shows no revenue growth, a significant drop in net income (-15.98% YoY), and a decline in EPS (-41.18% YoY). No recent news or congress trading data to support a positive sentiment.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income drop to -30.5 million (-15.98% YoY), and a significant EPS decline to -0.3 (-41.18% YoY). Gross margin remains at 0%.
Analysts are bullish, with multiple firms raising price targets recently (e.g., H.C. Wainwright to $25, Citi to $17, Piper Sandler to $22). Analysts expect a catalyst-rich period and see potential in ORIC-944 as a best-in-class treatment.
